Arcus Biosciences (RCUS) Stock Forecast & Price Target

Arcus Biosciences is viewed favorably because casdatifan targets the underlying HIF-2α biology of ccRCC, with KOL feedback suggesting meaningful differentiation from belzutifan, including 80%+ non-rebounding EPO suppression and manageable on-target anemia and hypoxia. The upcoming October ARC-20 readouts, including data from 121 monotherapy patients and roughly 45 cas plus cabozantinib patients, could de-risk late-line and frontline development while supporting broader use in 1L and post-IO settings. Beyond casdatifan, the company has additional optionality from quemliclustat in PRISM-1, while the pipeline breadth and a raised peak worldwide revenue estimate of $3.2B for cas in ccRCC reinforce the longer-term growth case.

Arcus Biosciences is viewed negatively because its outlook hinges on a pipeline that still faces meaningful clinical and regulatory uncertainty, especially for AB154 and domvanalimab, where efficacy or safety setbacks could materially delay or derail development. Commercially, the company may struggle against entrenched standards of care and future competitors, while tolerability issues such as higher anemia, hypoxia, and treatment discontinuations could limit adoption even if data remain competitive. Although Q2 financials showed a smaller net loss of $91M, or ($0.72) per share, and $775M in cash expected to fund operations until at least 2H:28, the absence of proven sales traction keeps execution risk elevated.